Exchange: NASDAQ·Updated 07:49 PM EST

NTRA News

News
all
press releases
AI-Powered Cancer Blood Tests Set the Stage for a Multibillion-Dollar Biotech Breakthrough
Emerging Technologies Target Earlier Detection of Breast and Colon Cancer as Global Demand for Advanced Diagnostics Accelerates   New York, NY – November 20, 2026 – A simple blood test that can detect cancer before symptoms appear is one of the most compelling developments taking shape in modern medicine. Biotechnology companies are now using artificial […] The post AI-Powered Cancer Blood Tests Set the Stage for a Multibillion-Dollar Biotech Breakthrough appeared first on Financial News Media.
Financial News Media
AI-Powered Cancer Blood Tests Set the Stage for a Multibillion-Dollar Biotech Breakthrough
Emerging Technologies Target Earlier Detection of Breast and Colon Cancer as Global Demand for Advanced Diagnostics Accelerates   New York, NY – November 20, 2026 – A simple blood test that can detect cancer before symptoms appear is one of the most compelling developments taking shape in modern medicine. Biotechnology companies are now using artificial […] The post AI-Powered Cancer Blood Tests Set the Stage for a Multibillion-Dollar Biotech Breakthrough appeared first on Financial News Media.
Financial News Media
More News
SELLAS Life Sciences Group, Moderna, Gilead Sciences, AbbVie, and Natera are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that use biotechnology to develop medicines, therapies, diagnostics, or other life-science produ...
MarketBeat
Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has been named the Best in Class winner in the Cancer, Screening & Early Detection category at the Digital Health Hub Foundation Digital Health & AI Awards. The recognition highlights the...
Business Wire
Moderna, AbbVie, CG Oncology, Natera, and Amgen are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that use biological science to develop or produce medicines, vaccines, diagnostics, and other health-related products. Fo...
MarketBeat
Natera (NASDAQ:NTRA) Chief Financial Officer Mike Brophy said the company has multiple paths to its $6 billion revenue target for 2029, citing growth in its Signatera cancer testing business and opportunities to improve reimbursement. Speaking at a UBS event, Brophy also addressed Natera's CEO tran...
MarketBeat
Natera, Inc. (Nasdaq:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has entered into a clinical collaboration agreement with Incyte (Nasdaq:INCY) for a new phase II study in colorectal cancer (CRC). The trial will evaluate INCA33890, Incytes investigational...
Business Wire
NTRA targets $6B in revenues by 2029 as Signatera testing surges, reimbursement expands and higher investments support its long-term growth strategy.
Zacks
Natera???s Q3 revenues jump 34.1%, beating estimates, while a wider-than-expected loss and surging oncology test volumes shape its raised 2026 sales outlook.
Zacks
The latest round of trades touched multiple ARK ETFs, spanning artificial intelligence, semiconductors, biotechnology, defense and space-related companies.
Stocktwits
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...
Nasdaq News: Markets

Advertisement|Remove ads.